Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation

Chemistry and Biology

Volumn 20, Issue 5, 2013, Pages 713-725

  Frumm, Stacey M ^a,b   Fan, Zi Peng ^a,b   Ross, Kenneth N ^c   Duvall, Jeremy R ^c   Gupta, Supriya ^c   Verplank, Lynn ^c   Suh, Byung Chul ^c   Holson, Edward ^c   Wagner, Florence F ^c   Smith, William B ^a   Paranal, Ronald M ^a   Bassil, Christopher F ^a,b   Qi, Jun ^a   Roti, Giovanni ^a,b   Kung, Andrew L ^d   Bradner, James E ^a,e   Tolliday, Nicola ^c   Stegmaier, Kimberly ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDOHYDROLASE INHIBITOR; ANTINEOPLASTIC AGENT; APICIDIN; BRD 3259; BRD 5100; BRD 5298; BRD 7914; BRD 8148; BRD 8430; ENTINOSTAT; GIVINOSTAT; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 1 INHIBITOR; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 2 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; ISOTRETINOIN; LACTAM DERIVATIVE; MRD 5298; PCI 34051; RETINOIC ACID; RNA; TACEDINALINE; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CHIRALITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; ENZYME INHIBITION; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOLECULAR LIBRARY; NEUROBLASTOMA CELL; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; LACTAMS; NEUROBLASTOMA; TRETINOIN;

EID: 84878237197     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2013.03.020     Document Type: Article

References (47)

1. O. Abdel-Wahab, and R.L. Levine Recent advances in the treatment of acute myeloid leukemia F1000 Med. Rep. 2 2010 55
2. L. Adès, A. Guerci, E. Raffoux, M. Sanz, P. Chevallier, S. Lapusan, C. Recher, X. Thomas, C. Rayon, S. Castaigne European APL Group Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience Blood 115 2010 1690 1696
3. S. Balasubramanian, J. Ramos, W. Luo, M. Sirisawad, E. Verner, and J.J. Buggy A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas Leukemia 22 2008 1026 1034
4. V. Banerji, S.M. Frumm, K.N. Ross, L.S. Li, A.C. Schinzel, C.K. Hahn, R.M. Kakoza, K.T. Chow, L. Ross, and G. Alexe The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia J. Clin. Invest. 122 2012 935 947
5. J.E. Bradner, R. Mak, S.K. Tanguturi, R. Mazitschek, S.J. Haggarty, K. Ross, C.Y. Chang, J. Bosco, N. West, and E. Morse Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease Proc. Natl. Acad. Sci. USA 107 2010 12617 12622
6. J.E. Bradner, N. West, M.L. Grachan, E.F. Greenberg, S.J. Haggarty, T. Warnow, and R. Mazitschek Chemical phylogenetics of histone deacetylases Nat. Chem. Biol. 6 2010 238 243
7. J.C. Bressi, A.J. Jennings, R. Skene, Y. Wu, R. Melkus, R. De Jong, S. O'Connell, C.E. Grimshaw, M. Navre, and A.R. Gangloff Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides Bioorg. Med. Chem. Lett. 20 2010 3142 3145
8. C.J. Chou, D. Herman, and J.M. Gottesfeld Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases J. Biol. Chem. 283 2008 35402 35409
9. D.C. Coffey, M.C. Kutko, R.D. Glick, S.L. Swendeman, L. Butler, R. Rifkind, P.A. Marks, V.M. Richon, and M.P. LaQuaglia Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro Med. Pediatr. Oncol. 35 2000 577 581
10. D.C. Coffey, M.C. Kutko, R.D. Glick, L.M. Butler, G. Heller, R.A. Rifkind, P.A. Marks, V.M. Richon, and M.P. La Quaglia The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid Cancer Res. 61 2001 3591 3594
11. S.J. Darkin-Rattray, A.M. Gurnett, R.W. Myers, P.M. Dulski, T.M. Crumley, J.J. Allocco, C. Cannova, P.T. Meinke, S.L. Colletti, and M.A. Bednarek Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase Proc. Natl. Acad. Sci. USA 93 1996 13143 13147
12. H. de Thé, M.M. Vivanco-Ruiz, P. Tiollais, H. Stunnenberg, and A. Dejean Identification of a retinoic acid responsive element in the retinoic acid receptor beta gene Nature 343 1990 177 180
13. H.M. el-Beltagi, A.C. Martens, P. Lelieveld, E.A. Haroun, and A. Hagenbeek Acetyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells - preclinical studies in a relevant rat model for human acute myelocytic leukemia Cancer Res. 53 1993 3008 3014
14. M.T. Epping, L. Wang, J.A. Plumb, M. Lieb, H. Gronemeyer, R. Brown, and R. Bernards A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors Proc. Natl. Acad. Sci. USA 104 2007 17777 17782
15. M. Fouladi, J.R. Park, C.F. Stewart, R.J. Gilbertson, P. Schaiquevich, J. Sun, J.M. Reid, M.M. Ames, R. Speights, and A.M. Ingle Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report J. Clin. Oncol. 28 2010 3623 3629
16. P.D. Gregory, K. Wagner, and W. Hörz Histone acetylation and chromatin remodeling Exp. Cell Res. 265 2001 195 202
17. C.K. Hahn, K.N. Ross, I.M. Warrington, R. Mazitschek, C.M. Kanegai, R.D. Wright, A.L. Kung, T.R. Golub, and K. Stegmaier Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation Proc. Natl. Acad. Sci. USA 105 2008 9751 9756
18. C.K. Hahn, J.E. Berchuck, K.N. Ross, R.M. Kakoza, K. Clauser, A.C. Schinzel, L. Ross, I. Galinsky, T.N. Davis, and S.J. Silver Proteomic and genetic approaches identify Syk as an AML target Cancer Cell 16 2009 281 294
19. E. Helman, K. Naxerova, and I.S. Kohane DNA hypermethylation in lung cancer is targeted at differentiation-associated genes Oncogene 31 2012 1181 1188
20. P. Jones, S. Altamura, P.K. Chakravarty, O. Cecchetti, R. De Francesco, P. Gallinari, R. Ingenito, P.T. Meinke, A. Petrocchi, and M. Rowley A series of novel, potent, and selective histone deacetylase inhibitors Bioorg. Med. Chem. Lett. 16 2006 5948 5952
21. W.K. Kelly, and P.A. Marks Drug insight: Histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid Nat. Clin. Pract. Oncol. 2 2005 150 157
22. F.E. Koehn, and G.T. Carter The evolving role of natural products in drug discovery Nat. Rev. Drug Discov. 4 2005 206 220
23. J.A. Kohler, J. Imeson, C. Ellershaw, and S.O. Lie A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy Br. J. Cancer 83 2000 1124 1127
24. D. Kong, and T. Yamori Advances in development of phosphatidylinositol 3-kinase inhibitors Curr. Med. Chem. 16 2009 2839 2854
25. F. Leoni, G. Fossati, E.C. Lewis, J.K. Lee, G. Porro, P. Pagani, D. Modena, M.L. Moras, P. Pozzi, and L.L. Reznikov The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo Mol. Med. 11 2005 1 15
26. J. Lotem, and L. Sachs Epigenetics and the plasticity of differentiation in normal and cancer stem cells Oncogene 25 2006 7663 7672
27. F. Lovering, J. Bikker, and C. Humblet Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 52 2009 6752 6756
28. B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, and R. Pazdur FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 2007 1247 1252
29. L.A. Marcaurelle, E. Comer, S. Dandapani, J.R. Duvall, B. Gerard, S. Kesavan, M.D. Lee 4th, H. Liu, J.T. Lowe, and J.C. Marie An aldol-based build/couple/pair strategy for the synthesis of medium- and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors J. Am. Chem. Soc. 132 2010 16962 16976
30. K.K. Matthay, J.G. Villablanca, R.C. Seeger, D.O. Stram, R.E. Harris, N.K. Ramsay, P. Swift, H. Shimada, C.T. Black, G.M. Brodeur Children's Cancer Group Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid N. Engl. J. Med. 341 1999 1165 1173
31. J.L. Methot, P.K. Chakravarty, M. Chenard, J. Close, J.C. Cruz, W.K. Dahlberg, J. Fleming, C.L. Hamblett, J.E. Hamill, and P. Harrington Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2) Bioorg. Med. Chem. Lett. 18 2008 973 978
32. S. Minucci, and P.G. Pelicci Retinoid receptors in health and disease: co-regulators and the chromatin connection Semin. Cell Dev. Biol. 10 1999 215 225
33. S. Modak, and N.K. Cheung Neuroblastoma: Therapeutic strategies for a clinical enigma Cancer Treat. Rev. 36 2010 307 317
34. O.M. Moradei, T.C. Mallais, S. Frechette, I. Paquin, P.E. Tessier, S.M. Leit, M. Fournel, C. Bonfils, M.C. Trachy-Bourget, and J. Liu Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity J. Med. Chem. 50 2007 5543 5546
35. A. Mühlethaler-Mottet, R. Meier, M. Flahaut, K.B. Bourloud, K. Nardou, J.M. Joseph, and N. Gross Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells Mol. Cancer 7 2008 55
36. J. Panicker, Z. Li, C. McMahon, C. Sizer, K. Steadman, R. Piekarz, S.E. Bates, and C.J. Thiele Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells Cell Cycle 9 2010 1830 1838
37. D. Peck, E.D. Crawford, K.N. Ross, K. Stegmaier, T.R. Golub, and J. Lamb A method for high-throughput gene expression signature analysis Genome Biol. 7 2006 R61
38. R.L. Piekarz, R. Frye, M. Turner, J.J. Wright, S.L. Allen, M.H. Kirschbaum, J. Zain, H.M. Prince, J.P. Leonard, and L.J. Geskin Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J. Clin. Oncol. 27 2009 5410 5417
39. J. Ramírez, and J. Hagman The Mi-2/NuRD complex: a critical epigenetic regulator of hematopoietic development, differentiation and cancer Epigenetics 4 2009 532 536
40. W. Rasheed, M. Bishton, R.W. Johnstone, and H.M. Prince Histone deacetylase inhibitors in lymphoma and solid malignancies Expert Rev. Anticancer Ther. 8 2008 413 432
41. P. Scaffidi, and T. Misteli Cancer epigenetics: from disruption of differentiation programs to the emergence of cancer stem cells Cold Spring Harb. Symp. Quant. Biol. 75 2010 251 258
42. S.L. Schreiber Target-oriented and diversity-oriented organic synthesis in drug discovery Science 287 2000 1964 1969
43. K. Stegmaier, K.N. Ross, S.A. Colavito, S. O'Malley, B.R. Stockwell, and T.R. Golub Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation Nat. Genet. 36 2004 257 263
44. T. Suzuki, T. Ando, K. Tsuchiya, N. Fukazawa, A. Saito, Y. Mariko, T. Yamashita, and O. Nakanishi Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives J. Med. Chem. 42 1999 3001 3003
45. J. Tsai, J.T. Lee, W. Wang, J. Zhang, H. Cho, S. Mamo, R. Bremer, S. Gillette, J. Kong, and N.K. Haass Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc. Natl. Acad. Sci. USA 105 2008 3041 3046
46. S.J. Whittaker, M.F. Demierre, E.J. Kim, A.H. Rook, A. Lerner, M. Duvic, J. Scarisbrick, S. Reddy, T. Robak, and J.C. Becker Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma J. Clin. Oncol. 28 2010 4485 4491
47. A.J. Wilson, E. Holson, F. Wagner, Y.L. Zhang, D.M. Fass, S.J. Haggarty, S. Bhaskara, S.W. Hiebert, S.L. Schreiber, and D. Khabele The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells Cancer Biol. Ther. 12 2011 484 493